Insmed CEO William Lewis Sells Over $700,000 in Shares

William Lewis, the CEO of Insmed, Inc. (NASDAQ: INSM), sold 4,096 shares of the company on January 6, 2024, generating a total of $709,959.68. The shares were sold at an average price of $173.33. Following this transaction, Lewis now directly holds 320,987 shares of the company, equating to a value of approximately $55,636,676.71. This represents a 1.26% decrease in his ownership stake.

The transaction was made public through a legal filing with the Securities and Exchange Commission (SEC), which can be accessed online. Insmed’s stock experienced a decline, trading down $5.73 to reach $170.27 during Thursday’s trading session, with a total of 2,588,589 shares exchanged. This volume surpassed the company’s average of 2,142,398 shares.

Current Financial Overview of Insmed

Insmed currently holds a market capitalization of $36.31 billion. The company has a P/E ratio of -27.51 and a beta of 1.08. Its recent performance indicates a 50-day moving average of $190.79 and a 200-day moving average of $151.24. Financial metrics show a current ratio of 4.63, a quick ratio of 4.34, and a debt-to-equity ratio of 0.59. Over the past year, the company’s stock has fluctuated significantly, with a 52-week low of $60.40 and a 52-week high of $212.75.

Several institutional investors have recently adjusted their holdings in Insmed. Darwin Global Management Ltd. increased its position by 5.8%, now owning 20,457,445 shares valued at $2.89 billion. Vanguard Group Inc. also elevated its stake by 13.0%, bringing its total to 19,935,820 shares, worth about $2.87 billion. Additionally, Capital International Investors raised its holdings by 1.0%, while Artisan Partners Limited Partnership increased its shares by an impressive 49.0%.

Analysts’ Perspectives and Future Projections

Equity research analysts have expressed optimism regarding Insmed’s future. Truist Financial initiated coverage with a “buy” rating and set a price target of $202.00. Evercore ISI reaffirmed an “outperform” rating with a target price of $180.00. Other notable forecasts include Redburn Partners, which established a target of $263.00, while UBS Group adjusted its target from $223.00 to $215.00, maintaining a “buy” rating.

The consensus from investment analysts shows two ratings as “Strong Buy,” twenty as “Buy,” one as “Hold,” and one as “Sell.” According to MarketBeat.com, Insmed currently holds a consensus rating of “Moderate Buy” with a price target averaging $205.64.

Insmed, headquartered in Bridgewater, New Jersey, specializes in developing and commercializing therapies for patients suffering from rare and serious diseases, particularly focusing on challenging pulmonary infections. Its primary marketed product, ARIKAYCE (amikacin liposome inhalation suspension), is designed to improve clinical outcomes for patients with limited treatment options.

As the biopharmaceutical landscape continues to evolve, the actions of key executives and analyst ratings will play a significant role in shaping the company’s trajectory and investor sentiment.